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Myelofibrosis (MF) is a Philadelphia chromosome–negative
myeloproliferative neoplasm that may occur as primary
myelofibrosis (PMF) or develop from progression of poly-
cythemia vera or essential thrombocythemia (post-poly-
cythemia vera or post-essential thrombocythemia MF, respec-
tively).1 The clinical hallmarks of MF are splenomegaly,
cytopenias, and debilitating symptoms associated with a
hypercatabolic state and systemic inflammation.2,3 Allogeneic
stem cell transplantation is the only potentially curative ther-
apy for MF. However, this therapy is recommended only for
a limited number of patients because of the high risk of treat-
ment-related morbidity and mortality as well as the poor
medical condition of patients.4
Dysregulation of the Janus kinase (JAK)–signal transducer
and activator of transcription (STAT) pathway is central to the
pathogenesis of MF.5-8 Approximately 65% of patients with
PMF carry the JAK2V617F gain-of-function mutation9 and 5% to
10% carry mutations in the thrombopoietin receptor gene
(MPL).10,11 Additional mutations leading to dysregulation of
the JAK-STAT signaling pathway have been characterized in
patients with PMF and other myeloproliferative neoplasms,
suggesting a high degree of complexity and heterogeneity in
disease pathogenesis.12,13 Recently, mutations in the CALR
gene encoding calreticulin were detected in approximately
67%14 to 82%15 of patients with essential thrombocythemia
and in 80%15 to 88%14 of patients with PMF who did not have
JAK2 or MPL mutations. The high frequency of CALR muta-
tions in these patients, along with evidence linking aberrant
calreticulin activity to JAK-STAT activation, supports a role
for calreticulin in the pathogenesis of myeloproliferative neo-
plasms.14 Despite the range of mutations, the central role of
the JAK-STAT pathway in myeloproliferative neoplasms has
provided the rationale for the development of targeted thera-
pies that inhibit JAK-STAT signaling.16,17
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In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant
improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall
survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis. This planned analy-
sis assessed the long-term efficacy and safety of ruxolitinib at a median follow-up of 149 weeks. At data cutoff,
approximately 50% of patients originally randomized to ruxolitinib remained on treatment whereas all patients
originally assigned to placebo had discontinued or crossed over to ruxolitinib. At week 144, mean spleen volume
reduction was 34% with ruxolitinib. Previously observed improvements in quality-of-life measures were sustained
with longer-term ruxolitinib therapy. Overall survival continued to favor ruxolitinib despite the majority of place-
bo patients crossing over to ruxolitinib [hazard ratio 0.69 (95% confidence interval: 0.46-1.03); P=0.067].
Exploratory analyses suggest that crossover may have contributed to an underestimation of the true survival dif-
ference between the treatment groups. Ruxolitinib continued to be generally well tolerated; there was no pattern
of worsening grade ≥3 anemia or thrombocytopenia with longer-term ruxolitinib exposure. These longer-term
data continue to support the efficacy and safety of ruxolitinib in patients with myelofibrosis. The study is registered
at clinicaltrials.gov: NCT00952289. 
Efficacy, safety, and survival with ruxolitinib in patients with 
myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek,1 Ruben A. Mesa,2 Jason Gotlib,3 Richard S. Levy,4 Vikas Gupta,5 John F. DiPersio,6 John V. Catalano,7
Michael W.N. Deininger,8* Carole B. Miller,9 Richard T. Silver,10 Moshe Talpaz,11 Elliott F. Winton,12 Jimmie H. Harvey, Jr,13
Murat O. Arcasoy,14 Elizabeth O. Hexner,15 Roger M. Lyons,16 Azra Raza,17 Kris Vaddi,4 William Sun,4 Wei Peng,4
Victor Sandor,4 and Hagop Kantarjian,1 for the COMFORT-I investigators
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Mayo Clinic, Scottsdale, AZ, USA; 3Stanford Cancer
Institute, Stanford, CA, USA; 4Incyte Corporation, Wilmington, DE, USA; 5Princess Margaret Cancer Center, University of Toronto, 
ON, Canada; 6Washington University School of Medicine, St. Louis, MO, USA; 7Frankston Hospital and Department of Clinical
Haematology, Monash University, Frankston, Australia; 8*Oregon Health and Science University, Portland, OR, USA; 9Saint Agnes
Cancer Institute, Baltimore, MD, USA; 10Weill Cornell Medical Center, New York, NY, USA; 11University of Michigan, Ann Arbor, MI,
USA; 12Emory University School of Medicine, Atlanta, GA, USA; 13Birmingham Hematology and Oncology, Birmingham, AL, USA;
14Duke University Health System, Durham, NC, USA; 15Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA,
USA; 16Cancer Care Centers of South Texas/US Oncology, San Antonio, TX, USA; 17Columbia Presbyterian Medical Center, New York,
NY, USA
*Currently at the Division of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt
Lake City, UT, USA
A complete list of the COMFORT-I investigators appears in the Appendix.
ABSTRACT
The oral JAK1 and JAK2 inhibitor ruxolitinib has been
evaluated in two phase III clinical trials in patients with
intermediate-2 or high-risk PMF (according to the
International Prognostic Scoring System)18 or post-poly-
cythemia vera MF or post-essential thrombocythemia MF
(according to the 2008 World Health Organization criteria):
the randomized, double-blind Controlled Myelofibrosis
Study with Oral JAK Inhibitor Treatment (COMFORT)-I19
study (www.clinicaltrials.gov: NCT00952289) and the ran-
domized, open-label COMFORT-II20 study (www.clinical-
trials.gov: NCT00934544), which compared the effects of
ruxolitinib with placebo or best available therapy, respec-
tively. Both studies showed that ruxolitinib treatment sig-
nificantly reduced splenomegaly and provided marked
improvements in MF-related symptoms and quality-of-
life (QOL) measures compared with controls, regardless
of JAK2V617F mutational status.19,20 The clinical benefit and
safety of ruxolitinib treatment in COMFORT-I and
COMFORT-II have been maintained with subsequent
longer-term follow-up.21-23 As anticipated, the effect of
JAK2 inhibition on hematopoiesis resulted in dose-depen-
dent anemia and thrombocytopenia. The majority of
these cytopenias occurred in the first 8 to 12 weeks of
treatment, and they were generally manageable with
dose reductions and/or red blood cell transfusions.
Subsequently, mean platelet counts stabilized and mean
hemoglobin levels gradually returned to a new steady
state just below baseline levels.21-24 Additionally, longer-
term follow-up of the COMFORT studies showed that
ruxolitinib treatment was associated with an overall sur-
vival advantage, despite the crossover design of these
studies.19,21-23 The objective of the current analysis is to
provide an update on the efficacy, focusing on overall sur-
vival, and safety of ruxolitinib in patients enrolled in
COMFORT-I at a median follow-up of approximately 3
years (149 weeks). 
Methods
Patients and study design
Detailed inclusion and exclusion criteria for the COMFORT-I
trial have been described previously.19 Briefly, patients with inter-
mediate-2 or high-risk PMF or post-polycythemia vera MF or post-
essential thrombocythemia MF and splenomegaly were random-
ized 1:1 to receive ruxolitinib or placebo orally twice a day (BID).
The starting dose of ruxolitinib was based on baseline platelet
count: 15 mg BID or 20 mg BID for baseline platelet counts of 100-
200×109/L or >200×109/L, respectively. Doses could be modified
per protocol.19
Crossover from the placebo arm to ruxolitinib was allowed
prior to the primary analysis based on defined criteria for worsen-
ing splenomegaly. Upon completion of the primary analysis, the
study was unblinded and all remaining patients receiving placebo
were allowed to cross over to ruxolitinib.19 Each participating site’s
institutional review board approved the protocol. The study spon-
sor analyzed and interpreted the data in collaboration with the
investigators. All authors had access to the aggregate data and any
additional analyses upon request. The study was conducted in
accordance with the International Conference on Harmonization
guidelines for Good Clinical Practice. All patients provided written
informed consent.19
Assessments
Timing and methods of assessment of spleen volume, symptom
burden, QOL measures, and adverse events, described previous-
ly,19 are detailed in the Online Supplementary Appendix.
Statistical analysis
This prospectively defined analysis was to occur when all
patients either reached the 144-week assessment or discontinued
participation in the study. Changes from baseline in spleen volume
and palpable spleen length were based on observed cases and
summarized descriptively. Durability of spleen volume reduction
was evaluated using the Kaplan-Meier method in patients who
achieved a ≥35% reduction from baseline. Loss of a ≥35% spleen
volume reduction was defined as the first <35% spleen volume
reduction from baseline that was also a ≥25% increase from nadir.
Overall survival was assessed using the Kaplan-Meier method for
the intent-to-treat population with patients assessed according to
their original randomized treatment. Survival time was measured
from the start of the study to last known status of the patient and
was not censored at time of discontinuation from randomized
treatment. The Cox proportional hazards model and log-rank test
were used to calculate the hazard ratio with 95% confidence inter-
val (CI) and P-value, respectively. The incidences of new-onset or
worsening grade ≥3 anemia and thrombocytopenia, and of new-
onset or worsening all-grade and grade ≥3 non-hematologic
adverse events, were calculated using the life table method.
Additional details on safety assessments are discussed in the
Online Supplementary Appendix.
To better understand the effect of crossover to ruxolitinib on
survival measurements, two exploratory analyses were per-
formed. The first used the rank-preserving structural failure time
(RPSFT) method, a statistical method used in oncology trials to
adjust for a possible crossover effect.25-27 The second analysis was
a parametric statistical modeling of overall survival using the gen-
eralized Gamma distribution,28,29 which fitted a three-parameter
regression model to the observed survival data to calculate the cor-
responding hazard of death for patients originally randomized to
ruxolitinib or placebo. Full details and description of the explorato-
ry analyses are described in the Online Supplementary Appendix.
Results
Patient disposition
At a median follow-up of 149 weeks (range, 19-175
weeks), 77 of the 155 patients (49.7%) originally random-
ized to ruxolitinib were still receiving ruxolitinib therapy. A
total of 111 of the 154 patients originally randomized to
placebo crossed over to ruxolitinib therapy. Of these 111
patients, 57 (51.4%) patients were still receiving ruxolitinib
therapy (Figure 1). In patients originally randomized to rux-
olitinib, discontinuation rates estimated using the Kaplan-
Meier method were 21% at year 1, 35% at year 2, and
51% at year 3. Reasons for discontinuation included dis-
ease progression (23.1%), adverse events (19.2%), death
(19.2%), and withdrawal of consent (15.4%) (Figure 1). 
The median exposure to ruxolitinib was 145 weeks for
patients originally randomized to ruxolitinib; for these
patients, the mean dose of ruxolitinib remained stable
after initial dose adjustments in the first 8 to 12 weeks of
therapy (Figure 2). For patients originally randomized to
placebo, the median exposure to placebo was 37 weeks.
For patients who crossed over to ruxolitinib from placebo,
the median time to crossover was 41 weeks. The median
exposure to ruxolitinib for patients who crossed over was
105 weeks, which, at the time of this analysis, was nearly
three times longer than their exposure to placebo.
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Efficacy
Reductions in spleen size were durable with longer-term
treatment with ruxolitinib. The mean percentage change
from baseline in spleen volume was −31.6% at week 24
(median −33.0%) and −34.1% at week 144 (median
−38.4%) (Figure 3A). The mean percentage change from
baseline in palpable spleen length was −43.4% at week 24
(median −41.2%) and −49.4% at week 144 (median
−50.0%) (Figure 3A). Assessment of palpable spleen
response using the International Working Group for
Myelofibrosis Research and Treatment (IWG-MRT) and
European LeukemiaNet (ELN) consensus criteria,30
showed that a palpable spleen response was achieved in
31.6% of ruxolitinib-treated patients compared with 2.0%
of patients in the placebo arm at week 24. At week 144,
palpable spleen response was achieved in 24.5% of
patients originally randomized to ruxolitinib. Fifty-nine
percent of patients (91/155) originally randomized to rux-
olitinib achieved a ≥35% reduction in spleen volume at
any time during the study follow-up. The majority of
COMFORT-I study: 3-year update on efficacy and safety
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Figure 1. Patient disposition. *For the placebo arm, there were three patients who were not evaluable for safety (n=151); these patients were
excluded from the calculation of the percentage of patients who discontinued (40/151). †Patients in the placebo group could cross over to
ruxolitinib prior to the primary analysis based on defined criteria for worsening splenomegaly. After the primary analysis had been completed,
the study was unblinded and all remaining patients receiving placebo were allowed to cross over to ruxolitinib. ‡The percentages of patients
who discontinued for the reasons listed are based on the number of patients who discontinued within the treatment group and not on the
total number of patients in the treatment group. BID: twice a day.
Figure 2. Mean daily dose of ruxolitinib over time in patients originally randomized to ruxolitinib. BID: twice a day; SEM: standard error of the
mean.
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patients achieved a ≥35% reduction from baseline in
spleen volume by week 12, the time of the first spleen vol-
ume assessment; in these patients, the probability of
maintaining a ≥35% spleen volume reduction for at least
132 weeks corresponded to 144 weeks on therapy. In this
analysis, the probability of maintaining a ≥35% spleen
volume reduction for at least 132 weeks was 0.53. Over
the course of follow-up, more than 80% of patients who
achieved a ≥35% reduction in spleen volume maintained
a reduction of at least 10% (Figure 3B), a reduction that
has been shown to be associated with meaningful
improvements in QOL and MF-related symptoms.21
Although the modified MF Symptom Assessment Form
version 2.0 was only assessed through week 24, improve-
ments in QOL measures, as assessed by the European
Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-Core 30 (EORTC QLQ-
C30), were maintained with longer-term therapy, includ-
ing improvements in global health status/QOL, fatigue,
role functioning, and physical functioning scales (Figure 4).
Overall survival
At the time of this analysis, 42 patients randomized to
ruxolitinib and 54 randomized to placebo had died. A list
of causes of death is provided in Online Supplementary
Table S1. With median follow-ups of 149.1 and 149.3
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Figure 3. (A) Percentage change in spleen size over time. Mean percentage change from baseline in spleen volume (left panel) and palpable
spleen length (right panel). (B) Durability of spleen volume reduction in patients originally randomized to ruxolitinib. The probability of main-
taining a spleen volume reduction in patients who achieved a ≥35% decrease in spleen volume over the course of the study is shown. Also
shown is the probability of maintaining a ≥10% spleen volume reduction — a spleen volume reduction that has been shown to be associated
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N. of patients at risk
weeks for the ruxolitinib and placebo arms, respectively,
the hazard ratio for overall survival continued to favor
patients originally randomized to ruxolitinib compared
with those originally randomized to placebo [hazard ratio
0.69 (95% CI: 0.46-1.03); P=0.067] (Figure 5A). Although
the hazard ratio continued to favor ruxolitinib, the P-value
no longer reached nominal significance at the P=0.05 level.
Therefore, exploratory analyses were conducted to assess
the potential impact of crossover and substantially longer
exposure to ruxolitinib than placebo among patients orig-
inally randomized to placebo. The RPSFT method esti-
mated a hazard ratio of 0.36 (95% CI: 0.204-1.035) (Figure
5B). Exploratory modeling of survival using a generalized
Gamma distribution showed that the hazard of death in
patients originally randomized to placebo was initially
higher than that in patients randomized to ruxolitinib.
This hazard subsequently decreased over time, correspon-
ding with an increased proportion of patients who crossed
over to ruxolitinib (Online Supplementary Figure S1). 
Safety
As expected given the role of JAK2 in erythropoietin and
thrombopoietin signaling, anemia and thrombocytopenia
were the most common adverse events observed with
ruxolitinib therapy. The incidence of new-onset or wors-
ening grade 3 or 4 anemia and thrombocytopenia were
highest during the first 6 months of therapy and decreased
with longer-term ruxolitinib treatment (Figure 6A).
Consistent with this observation, mean hemoglobin levels
and platelet counts in ruxolitinib-treated patients
decreased in the first 8 to 12 weeks. Mean hemoglobin
levels reached a nadir in this time frame, then subsequent-
ly increased to a new steady-state level by week 24 and
remained stable through the course of longer-term follow-
up. Mean platelet counts remained stable with longer-
term follow-up after the initial decrease (Figure 6B). Since
the last reported analysis at a median follow-up of 102
weeks,21 no additional patients have discontinued the
study because of anemia or thrombocytopenia. 
The most common non-hematologic adverse events
that occurred more frequently with ruxolitinib than with
placebo in the primary analysis were ecchymosis (18.7%),
dizziness (14.8%), and headache (14.8%).19 When adjust-
ed for exposure to ruxolitinib, the incidence of these
adverse events as well as other non-hematologic events
decreased with longer-term therapy (Table 1), as did rates
of grade ≥3 adverse events (Online Supplementary Table
S2). Urinary tract infections and herpes zoster were infec-
tions that occurred in patients receiving ruxolitinib during
randomized treatment;31 however, no increase in inci-
dence was noted with long-term ruxolitinib therapy. A
comprehensive analysis of MedDRA preferred terms
associated with these infections showed that the inci-
dence of urinary tract infections per the life table method
was 10.5% (n=15) for 0 to <12 months, 6.7% (n=7)  for 12
to <24 months, 7.7% (n=6)  for 24 to <36 months, and
6.0% (n=2) for ≥36 months in patients originally random-
ized to ruxolitinib. Two urinary tract infections were
grade ≥3, one occurring between months 12 and 24 and
one occurring between months 24 and 36. The incidences
of herpes zoster were 2.1% (n=3) for 0 to <12 months,
3.5% (n=4) for 12 to <24 months, 3.4% (n=3) for 24 to
<36 months, and 0% for ≥36 months in patients originally
randomized to ruxolitinib; all herpes zoster infections
were grade 1 or grade 2. No other opportunistic infections
occurred with long-term ruxolitinib therapy. The overall
pattern of adverse events observed after treatment inter-
ruption or discontinuation continued to support the
absence of a specific withdrawal effect (Online
Supplementary Tables S3 and S4). 
Four new cases of acute myeloid leukemia have been
reported since the previous analysis (two in patients orig-
inally randomized to ruxolitinib; two in patients originally
randomized to placebo who developed acute myeloid
leukemia after crossing over to ruxolitinib), for a total of
eight cases since the study was started (four in patients
originally randomized to ruxolitinib; four in patients orig-
inally randomized to placebo). The rate of leukemic trans-
formation per person-year of ruxolitinib exposure was
0.0121/person-year and 0.0233/person-year in patients
originally randomized to ruxolitinib or placebo, respec-
tively.
Discussion
In this planned analysis of the COMFORT-I study with
a median follow-up of 149 weeks, ruxolitinib treatment
continued to be associated with durable reductions in
spleen volume and improvements in QOL measures.
Longer-term follow-up revealed a slight decline in QOL
measures. However, this may be related to the well-
described phenomenon of “response shift,” which reflects
the changes in patients’ perspective on key QOL domains
owing to repeated testing over the course of treatment.32
Despite this potential for response shift, the EORTC
QLQ-C30 scales indicated that QOL was still improved
COMFORT-I study: 3-year update on efficacy and safety
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Table 1. Incidence of new-onset all-grade non-hematologic adverse events
regardless of causality.
Ruxolitinib
0 to <12 12 to <24 24 to <36 ≥36 
months months months months
Incidence, % (n=155) (n=130) (n=103) (n=82)
Fatigue 29.0 15.2 15.3 7.7
Diarrhea 27.8 6.7 10.8 3.9
Ecchymosis 21.2 10.4 5.7 0
Peripheral edema 21.3 8.4 12.6 0
Dyspnea 19.2 10.2 2.9 3.3
Dizziness 18.1 10.4 3.0 3.5
Pain in extremity 18.0 6.2 4.2 3.3
Headache 16.6 5.1 2.7 0
Nausea 16.6 6.8 5.1 5.9
Constipation 14.5 8.6 10.1 9.0
Abdominal pain 13.8 5.7 3.6 0
Insomnia 13.8 5.7 3.7 0
Vomiting 13.7 2.8 2.4 5.5
Pyrexia 13.5 7.3 8.5 2.9
Cough 13.1 13.3 4.0 6.0
Arthralgia 11.8 5.8 6.6 6.3
Upper respiratory tract 
infection 7.7 11.1 4.0 3.2
The percentage of patients for each event was based on the effective sample size of the time inter-
val (number of patients at risk at the beginning of the interval minus half of the censored patients
during the time interval). An adverse event is included if the incidence was >10% at any yearly
interval.
relative to baseline with longer-term ruxolitinib treatment. 
The hazard ratio for overall survival continued to favor
ruxolitinib compared with placebo despite the majority of
patients having crossed over from placebo to ruxolitinib,
although statistical significance was not maintained.
Although the rate of discontinuation from randomized
treatment was higher in the placebo group than in the rux-
olitinib group at the primary analysis,19 follow-up for over-
all survival was well balanced between the two treatment
arms. The exposure to ruxolitinib in patients who crossed
over from placebo was substantially longer than their
exposure to placebo (105 weeks versus 37 weeks for medi-
an exposure to ruxolitinib and placebo, respectively), thus
confounding the comparison of overall survival between
the two treatment groups in favor of the placebo arm. To
understand the effect of crossover to active treatment in
placebo-controlled studies, several statistical methods
have been developed. The exploratory analysis of overall
survival using the RPSFT showed that crossover from
placebo may have led to an underestimation of overall sur-
vival difference. This is consistent with findings from
other oncology trials using this method, in which
crossover to active treatment may also have led to an
underestimation of the survival difference between place-
bo and active treatment.26,27 Consistent with the RPSFT
analysis, the exploratory analysis using the generalized
Gamma function showed that the probability of death in
the placebo group was initially higher than in the original
ruxolitinib-treated group, and that this probability
decreased over time as patients originally assigned to
placebo crossed over to receive ruxolitinib treatment. This
finding is expected for a crossover trial in which the active
treatment has a positive impact on survival.29 Although the
specific mechanism underlying the prolonged survival
observed in patients originally randomized to ruxolitinib
in COMFORT-I is unknown, the reductions in spleen vol-
ume and improvements in functional status and QOL
measures may have had a modulatory effect on the com-
mon causes of death not related to disease progression in
patients with MF.18
Consistent with our findings, a separate report of the
COMFORT-II study showed that long-term ruxolitinib
therapy was associated with an overall survival advantage
relative to best available therapy at 3 years of follow-up
[hazard ratio 0.48 (95% CI: 0.28-0.85); P=0.009].23 Similar
to what was observed in COMFORT-I, this analysis is
likely biased against ruxolitinib as a result of the patients
crossing over from best available therapy. However, in
COMFORT-II the confounding effect of crossover is less
severe than in COMFORT-I because of the longer expo-
sure to best available therapy prior to crossover to ruxoli-
tinib (median time of follow-up at primary analysis: 52
weeks in COMFORT-II20 and 32 weeks in COMFORT-I19).
Additionally, a pre-specified analysis of overall survival
from pooled data from COMFORT-I and COMFORT-II
supports an overall survival benefit of ruxolitinib com-
pared with controls [hazard ratio 0.65 (95% CI: 0.46-0.90);
P=0.01]. Further exploratory RPSFT analysis of pooled sur-
vival data from the COMFORT studies suggests an under-
estimation of the survival difference between treatment
groups because of the effect of crossover [RPSFT-corrected
hazard ratio 0.29 (95% CI: 0.13-0.63); P=0.01].33
In this 3-year update of COMFORT-I, ruxolitinib treat-
ment demonstrated durable efficacy at doses that were sta-
ble over the course of long-term follow-up. Dose adjust-
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Figure 4. Mean change in quality-of-life (QOL) measures assessed
using the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire-Core 30. The figures shown are
global health status, two functional domains (role and physical func-
tioning), and symptom scores for fatigue, a key symptom affecting
QOL in patients with myelofibrosis. Arrows indicate improvement. 
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ments occurred primarily in the first 8 to 12 weeks of the
study, particularly in patients with baseline platelet counts
between 100×109/L and 200×109/L who received a starting
dose of 15 mg BID. By week 24, the median titrated dose
was 10 mg BID for this subgroup of patients and 20 mg BID
for those with a baseline platelet count >200×109/L; doses
stabilized with longer-term treatment.24
Overall, no unexpected safety or tolerability issues were
detected during longer-term ruxolitinib treatment. As
expected, anemia and thrombocytopenia mainly occurred
early in the course of treatment, and there was no pattern
of worsening of these events with longer-term exposure to
ruxolitinib in patients who remained in the study. An addi-
tional analysis of the incidence of new-onset or worsening
grade ≥3 anemia and thrombocytopenia that counted
patients who experienced both grade 3 and 4 events in each
grade yielded similar results.34 As previously noted, the ini-
tial increases in anemia and thrombocytopenia observed in
the first 6 months of treatment and the subsequent decline
in the incidence of these events was consistent with the
timing of ruxolitinib dose adjustments. In ruxolitinib-treat-
ed patients, the rate of red blood cell transfusions increased
in the first 8 weeks of treatment and later declined to levels
similar to those in the placebo arm by week 36 and
remained stable thereafter. This was consistent with the
observed pattern of hemoglobin levels, which initially
decreased and subsequently stabilized at a new steady
state.24 Although cases of urinary tract infections and herpes
zoster infections were observed in patients randomized to
ruxolitinib, the incidence of these infections did not
increase with longer-term therapy. As previously described,
systematic review of the pattern of adverse events observed
after treatment interruption or discontinuation in this analy-
sis fails to support a specific withdrawal syndrome other
than return to baseline disease.19,21
Longer-term ruxolitinib treatment did not affect the risk
of transformation to acute myeloid leukemia. The rates of
leukemic transformation per person-year of ruxolitinib
exposure in patients originally randomized to ruxolitinib
(0.0121/person-year) and in those originally randomized
to placebo after they crossed over to ruxolitinib
(0.0233/person-year) showed no evidence of an increased
COMFORT-I study: 3-year update on efficacy and safety
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Figure 5. (A) Overall survival in the intent-to-treat population as assessed by the Kaplan-Meier method. (B) Overall survival in the intent-to-treat
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risk of leukemic transformation when compared with the
rate derived from a historical control population of 310
patients with MF (0.038/person-year).35
In summary, patients receiving ruxolitinib treatment for
a median of 3 years in the COMFORT-I study maintained
durable reductions in spleen volume and meaningful
improvements in QOL measures. Overall survival contin-
ued to favor those patients originally randomized to rux-
olitinib compared with those originally randomized to
placebo despite the majority of those assigned to placebo
crossing over to ruxolitinib treatment. This crossover may
have contributed to an underestimation of the true sur-
vival difference between the two treatment arms.
Ruxolitinib treatment continued to be generally well toler-
ated, and the incidence of new-onset grade 3 or 4 anemia
and thrombocytopenia decreased with longer-term thera-
py. Collectively, long-term analyses from COMFORT-I
and COMFORT-II continue to support the sustained effi-
cacy and safety of ruxolitinib and provide evidence to sup-
port a meaningful ability of ruxolitinib to improve overall
survival in patients with MF, and possibly modify the
course of the disease.
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Figure 6. (A) Incidence of new-onset or worsening grade 3 or 4 anemia and thrombocytopenia over time. (B) Mean hemoglobin level and
platelet count and hemoglobin level over time. *All patients receiving placebo at the primary analysis crossed over or discontinued within 3
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